Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update

Eyenovia, Inc.

Announced FDA approval of Mydcombi™, a fixed dose combination of tropicamide and phenylephrine for mydriasis, the first FDA approved product to utilize the Optejet^®

Received feedback from FDA on its Phase 3 Microline presbyopia candidate that provides a clear and efficient path forward for the program

Entered into co-development agreement with Formosa Pharmaceuticals for the potential development of new topical ophthalmic therapeutics

Company to host conference call and webcast today, May 11, at 4:30 pm ET

NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing the Optejet delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced its financial and operating results for the first quarter ended March 31, 2023.

First Quarter 2023 and Recent Business Developments

• Announced U.S. Food and Drug Administration (FDA) approval of Mydcombi, the Company’s proprietary combination microdose formulation of tropicamide and phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired. Please see the full prescribing information at www.mydcombi.com.

• Received feedback from FDA on its Phase 3 Microline presbyopia candidate that provides a clear and efficient path forward for the program.

• Entered into a development collaboration agreement with Formosa Pharmaceuticals to combine Eyenovia’s Optejet with Formosa’s APNT nanoparticle formulation platform for the potential development of new topical ophthalmic therapeutics.

• Announced positive results from a research study, conducted in collaboration with Tufts Medical Center, demonstrating the superiority of the Optejet versus standard eye drops in the administration of the anti-glaucoma medication latanoprost preserved with benzalkonium chloride (BAK). Optejet was found to achieve a therapeutic dose of latanoprost with significantly less exposure to excess drug and harmful preservatives than can be achieved using conventional drops. These results were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2023 annual meeting in April.

• Continued to build out its manufacturing facilities in Redwood City, CA and Reno, NV, which is on track to come online during the third quarter of 2023.

• Licensing partners Bausch+Lomb and Arctic Vision continued to enroll patients in their respective Phase 3 studies of Micropine (US and China) and Microline (China).

• Ended the first quarter of 2023 with approximately $18.5 million in total cash and cash equivalents. In addition, with the approval of Mydcombi, the Company has the ability to draw down an additional $5 million on its credit facility with Avenue Capital before July 31, 2023.
  

Michael Rowe, Chief Executive Officer, commented, "We are proud to be delivering on our commitments in 2023 with the recently announced FDA approval of Mydcombi, our first approved product dispensed using our Optejet technology. We believe the Optejet will transform the way that topical eye drugs are developed and delivered, and this FDA approval marks a significant milestone in its evolution. It is also an important achievement in the context of our current and future partnerships, providing a template for the development of additional ophthalmic therapies administered via the Optejet in high-value ophthalmic indications."

"Regarding our pre-NDA Microline program for presbyopia, we received clear feedback from the FDA that provides an efficient path forward for the program. We are in the process of completing the build-out and validation of our Redwood City manufacturing facility and remain on track to commence the manufacture of launch batches early next year. In the interim, we plan to conduct supportive human factors testing and clinical work demonstrating the usability of the Gen-2 Optejet device, which has been optimized for in-home use.”

“With one product approved, and line-of-sight toward a second, we have reached a true inflection point in the evolution of our company. Having an FDA approved product not only provides critical validation of our Optejet technology for our own advanced clinical programs, but also our partnerships as well. To that end, we continue to advance discussions with additional partners that could potentially assess the utility of Optejet in very large indications such as glaucoma and dry eye, among others. I am pleased with our progress to date and look forward to initial commercial sales of Mydcombi this summer together with continued clinical and regulatory progress for us and our partners.”

First Quarter 2023 Financial Review

For the first quarter of 2023, net loss was approximately $(5.7) million, or $(0.15) per share compared to a net loss of approximately $(7.3) million, or $(0.24) per share, for the first quarter of 2022.

Research and development expenses totaled approximately $2.5 million for the first quarter of 2023 as compared to $3.7 million for the first quarter of 2022.

For the first quarter of 2023, general and administrative expenses were approximately $2.9 million, compared to $3.5 million for the first quarter of 2022.

Total operating expenses for the first quarter of 2023 were approximately $5.5 million compared to $7.2 million for the first quarter of 2022.

As of March 31, 2023, the Company’s cash and cash equivalents were approximately $18.5 million compared to $22.9 million as of December 31, 2022. In addition, with the approval of Mydcombi, the Company has the ability to draw down an additional $5 million on its credit facility with Avenue Capital before July 31, 2023.

Conference Call and Webcast

The conference call is scheduled to begin at 4:30 pm ET today, May 11. Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international). A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.eyenovia.com.

To access the Call me™ feature, which avoids having to wait for an operator, click here.

After the live webcast, the event will be archived on Eyenovia’s website for one year.

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics. Eyenovia is currently focused on the commercialization of Mydcombi and the late-stage development of microdosed medications for presbyopia and myopia progression. For more information, visit www.eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com

Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363

Eyenovia Media Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com

EYENOVIA, INC.
Condensed Balance Sheets
			March 31,				December 31,
			2023				2022
			(unaudited)
Assets
Current Assets:
	Cash and cash equivalents		$	18,466,322			$	22,863,520
	Deferred clinical supply costs			3,352,645				2,284,931
	License fee and expense reimbursements receivable			973,677				1,183,786
	Security deposits, current			119,550				119,550
	Prepaid expenses and other current assets			2,011,884				1,190,719
		Total Current Assets		24,924,078				27,642,506
Property and equipment, net				2,152,861				1,295,115
Security deposits, non-current				80,874				80,874
Operating lease right-of-use asset				1,508,158				1,291,592
Equipment deposits				643,513				726,326
		Total Assets	$	29,309,484			$	31,036,413
Liabilities and Stockholders' Equity
Current Liabilities:
	Accounts payable		$	1,402,076			$	1,428,283
	Accrued compensation			637,189				1,747,191
	Accrued expenses and other current liabilities			460,143				503,076
	Operating lease liabilities - current portion			472,901				484,882
	Notes payable - current portion, net of debt discount of $123,480
	and $33,885 as of March 31, 2023 and December 31, 2022, respectively			1,218,963				174,448
	Convertible notes payable - current portion, net of debt discount of $123,480
	and $33,885 as of March 31, 2023 and December 31, 2022, respectively			709,853				174,448
		Total Current Liabilities		4,901,125				4,512,328
Operating lease liabilities - non-current portion				1,133,948				907,644
Notes payable - non-current portion, net of debt discount of $648,889
and $813,229 as of March 31, 2023 and December 31, 2022, respectively				3,730,278				4,190,938
Convertible notes payable - non-current portion, net of debt discount of $648,889
and $813,229 as of March 31, 2023 and December 31, 2022, respectively				3,730,278				4,190,938
		Total Liabilities		13,495,629				13,801,848
Stockholders' Equity:
	Preferred stock, $0.0001 par value, 6,000,000 shares authorized;
	0 shares issued and outstanding as of March 31, 2023 and
	December 31, 2022			-				-
	Common stock, $0.0001 par value, 90,000,000 shares authorized;
	37,991,746 and 36,668,980 shares issued and outstanding
	as of March 31, 2023 and December 31, 2022, respectively			3,799				3,667
	Additional paid-in capital			139,779,885				135,461,361
	Accumulated deficit			(123,969,829	)			(118,230,463	)
		Total Stockholders' Equity		15,813,855				17,234,565
		Total Liabilities and Stockholders' Equity	$	29,309,484			$	31,036,413

 

EYENOVIA, INC.
Condensed Statements of Operations
(unaudited)
			For the Three Months Ended
			March 31,
			2023				2022
Operating Expenses:
	Research and development		$	2,521,950			$	3,712,584
	General and administrative			2,936,886				3,474,965
		Total Operating Expenses		5,458,836				7,187,549
		Loss From Operations		(5,458,836	)			(7,187,549	)
Other Income (Expense):
	Other income (expense), net			70,993				(7,073	)
	Interest expense			(454,003	)			(145,237	)
	Interest income			102,480				194
		Net Loss	$	(5,739,366	)		$	(7,339,665	)
Net Loss Per Share - Basic and Diluted			$	(0.15	)		$	(0.24	)
Weighted Average Number of Common
	Shares Outstanding
		- Basic and Diluted		37,410,587				30,008,194